GlassScriptPhysician profile
Nojan Valadi
NPI 1417171737
$219,200.90
in general payments reported to CMS, 2019-2025
38 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104K · 2020: $23K · 2021: $24K · 2022: $23K · 2023: $6,747 · 2024: $38K · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Travel and Lodging: $9,233 · Food and Beverage: $3,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,000.00 |
| Travel and Lodging | $9,232.60 |
| Food and Beverage | $3,713.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $131,499.95 | 2019-2024 | Xarelto |
| Genentech USA, INC. | $79,210.15 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Portola Pharmaceuticals, LLC | $2,515.82 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $1,557.46 | 2019-2025 | Ultomiris |
| Abbvie INC. | $633.75 | 2021-2025 | Qulipta, Ubrelvy |
| Ucb, INC. | $523.66 | 2022-2024 | Briviact, Fintepla |
| Astrazeneca Pharmaceuticals LP | $473.35 | 2022-2023 | Andexxa |
| Greenwich Biosciences, INC. | $343.94 | 2019-2021 | |
| Pfizer INC. | $271.36 | 2025 | |
| Argenx US, INC. | $224.71 | 2023-2025 | Vyvgart Hytrulo |
| Eisai INC. | $205.50 | 2019-2025 | |
| Emd Serono, INC. | $175.24 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $167.55 | 2019-2025 | Nuplazid |
| Biogen, INC. | $151.30 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Amgen INC. | $143.31 | 2019-2025 | Uplizna |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nojan Valadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.